Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSURE long-term open-label safety study of seladelpar in primary biliary cholangitis
MOH_2021-07-19_010151Phase 3Not yet recruiting
- Sponsor
- CymaBay Therapeutics
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of seladelpar in primary biliary cholangitis (PBC) (2 arms), sponsored by CymaBay Therapeutics. Primary endpoint: Long-term safety and tolerability of seladelpar. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on MOH_2021-07-19_010151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-19_010151.